The Unmet Needs of Tumors in the Treatment Landscape

Based upon the tumor subtype there are different unmet needs that we have for patients with triple negative breast cancer. There's been a real advance even in the early state setting with immunotherapy but for our patients with metastatic disease there remains this unmet need for having new targets and new drugs. The potential role of circulating tumor DNA may come in not just prognostically but also predictably, which could move the field forward.